pazopanib drug pathway pazopanib pharmacodynamics pathway 2012-10-19T16:14:15Z PW:0001134 The pathway of pazopanib-target interaction and of the biochemical or physiological responses to drug. Pazopanib is a selective multikinase inhibitor approved for the treatment or renal cell carcinoma. The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can cause differences in the response of the organism to the drug. pathway vpetri